1 completed, 1 unknown. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Unknown 1 |
Follow Olanzapine: new trials by email Literature Review of Olanzapine trials Research Report on Olanzapine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication? Semaglutide, 1.34 mg/mL, Semaglutide-placebo - Metabolic Disturbance, Schizophrenia | Phase 4 | Unknown | Anders Fink-Jensen, MD, DMSci | 104 | 2021-09-01 | 2024-09-25 |
| Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients Flupentixol, Multi-acting receptor-targeted antipsychotics (MARTAs) - Schizophrenia; Psychosis, Metabolic Syndrome | Phase 4 | Completed | Taichung Veterans General Hospital | 30 | 2019-12-19 | 2021-05-24 |
Schizophrenia (2) · Central Nervous System Diseases (1) · Diabetes Mellitus, Type 2 (1) · Metabolic Syndrome (1) · Psychotic Disorders (1)
Glucose Metabolism Disorders (2) · Mental Disorders (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Schizophrenia Spectrum and Other Psychotic Disorders (2) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Hyperinsulinism (1) · Insulin Resistance (1) · Nervous System Diseases (1)
Flupenthixol (1) · semaglutide (1)
Anders Fink-Jensen, MD, DMSci (1) · Taichung Veterans General Hospital (1)
Denmark (1) · Taiwan (1)
Anders Fink-Jensen, MD (1) · Chia-Jui Tsai, M.D. (1)